ArriVent BioPharma, Inc.

For the period ended Sep 30, 2026. Filed Nov 9, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 9, 2026

AVBP$14.16+3.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Balance Sheets

(in thousands, except share and per share data)


· · September 30, · · December 31,
· · 2026 · · 2025
Assets · · · ·
Current assets: · · · ·
Cash and cash equivalents	$113,583	$45,540
Short-term investments	279,640	267,281
Prepaid expenses and other current assets	23,392	20,076
Total current assets	416,615	332,897
Right of use assets – operating leases	302	13
Deferred offering costs	38	69
Other assets	134	190
Total assets	$417,089	$333,169

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$2,615	$5,934
Accrued expenses	20,742	19,997
Operating lease liabilities	256	14
Total liabilities	23,613	25,945

Commitments and contingencies (Note 8)

Stockholders’ equity:
Preferred stock $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding	—	—
Common stock $0.0001 par value, 200,000,000 shares authorized; 51,212,170 and 42,452,251 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively	5	4
Additional paid-in capital	932,104	711,847
Accumulated deficit	(538,167)	(404,641)
Accumulated other comprehensive income (loss)	(466)	14
Total stockholders’ equity	393,476	307,224
Total liabilities and stockholders’ equity	$417,089	$333,169

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.